Stay updated on Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference0.5%
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.4%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.7%
- Check67 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check81 days agoChange DetectedThe page has removed significant details about a Phase 1b study evaluating lenvatinib and pembrolizumab for hepatocellular carcinoma, including the study's design, objectives, and inclusion/exclusion criteria, while adding a new identifier and revision number.SummaryDifference7%
Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.